title: Subjective quality of life and sexual functioning after germ-cell tumour therapy.
abstract: To evaluate the influence of germ-cell tumour therapy on sexual functioning and subjective quality of life (QL). To investigate the communication about sexual problems between patients, their partners, and doctors. In all, 474 patients treated for germ-cell tumours at the Department of Internal Medicine III, Ludwig-Maximilians-University Munich, from 1979 to 2000 were asked to complete a self-report questionnaire concerning psychosocial dimensions and subjective QL (QLS; Henrich and Herschbach, 2000). In total, 341 patients returned a completed questionnaire (response rate, 71.9%). The median age at survey was 41.9 years and the median follow-up period after therapy was 9.6 years. Persisting sexual sequelae were lower than in the current literature: decreased sexual desire (7.1%), erection (10.0%), orgasm (10.2%), ejaculation (28.8%), sexual activity (8.5%), and sexual satisfaction (4.8%). In QL the satisfaction with 'friends/acquaintances' (P<0.001) and 'family life/children' (P<0.001), is lower than in the healthy population. Correlations between functional scales and subjective QL were highly significant. There is a strong correlation between sexual satisfaction and global life satisfaction (Spearman's Rho: 0.48; P<0.01). A total of 61.4% of patients were not offered communication about sexual problems by their doctors and 21.2% were unable to talk with their partner about sexual issues. In conclusion, moderating psychosocial variables (e.g. personality factors, cognitive processes) should be investigated to clarify the relationship between life satisfaction (subjective QL) and functional impairments. Communication about sexual problems should be offered as a standard to patients treated for germ-cell tumours.
authors.affiliation: Department of Internal Medicine III, Ludwig-Maximilians-University, Marchioninistrasse 15, 81377 Munich, Germany. martin@fegg.de
authors.forename: M J
authors.initials: MJ
authors.lastname: Fegg
authors.forename: A
authors.initials: A
authors.lastname: Gerl
authors.forename: T C
authors.initials: TC
authors.lastname: Vollmer
authors.forename: U
authors.initials: U
authors.lastname: Gruber
authors.forename: C
authors.initials: C
authors.lastname: Jost
authors.forename: S
authors.initials: S
authors.lastname: Meiler
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000523:psychology; D006801:Humans; D008197:Lymph Node Excision / Q000009:adverse effects / Q000523:psychology*; D008297:Male; D008875:Middle Aged; D009373:Neoplasms, Germ Cell and Embryonal / Q000523:psychology / Q000628:therapy*; D009919:Orchiectomy / Q000009:adverse effects / Q000523:psychology*; D011584:Psychology; D011788:Quality of Life; D012187:Retroperitoneal Space; D012725:Sexual Behavior; D012735:Sexual Dysfunction, Physiological / Q000209:etiology / Q000523:psychology; D020018:Sexual Dysfunctions, Psychological / Q000209:etiology / Q000523:psychology; D013736:Testicular Neoplasms / Q000523:psychology / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents